These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 38564097)

  • 1. A Phase I Clinical Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of GB221 Injection and Trastuzumab (Herceptin
    Zhu Y; Li C; Chen L; Liu H; Ou L; Li T; Wang X; Wang T; Tian J; Liang X; Hu Z; Zhan Y; Xiao S; Wang X; Li Y; He J; Zheng Q; Song H; Li X; Fang Y
    Eur J Drug Metab Pharmacokinet; 2024 May; 49(3):383-392. PubMed ID: 38564097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized phase I clinical trial comparing the pharmacokinetic, safety, and immunogenicity of potential biosimilar recombinant human HER2 monoclonal antibody for injection and trastuzumab in healthy Chinese adults.
    Wang J; Niu S; Dong W; Wei L; Ou L; Zhang T; Zhang L; Nie X; Wang Q; Shen T; Wang Q; Xia L; Liu G; Jin J; Zheng Q; Song H; Fang Y
    Expert Opin Investig Drugs; 2020 Jul; 29(7):755-762. PubMed ID: 32594779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized Phase I pharmacokinetic trial comparing the potential biosimilar trastuzumab (SIBP-01) with the reference product (Herceptin®) in healthy Chinese male volunteers.
    Zhou H; Cao S; Zhu X; Xie J; Fan L; Ge Q; Wang Y; Zhu J; Liu Y; Shao Z; Shan R; Liu B; Wang H; Ding L
    Expert Opin Drug Metab Toxicol; 2020 Oct; 16(10):997-1003. PubMed ID: 32847423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, double-blind, parallel pharmacokinetic study comparing the trastuzumab biosimilar candidate, AryoTrust®, and reference trastuzumab in healthy subjects.
    Farmahini Farahani M; Maghzi P; Jafari Aryan N; Payandemehr B; Soni M; Azhdarzadeh M
    Expert Opin Investig Drugs; 2020 Dec; 29(12):1443-1450. PubMed ID: 33016783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A pharmacokinetics phase 1 bioequivalence study of the trastuzumab biosimilar MYL-1401O vs. EU-trastuzumab and US-trastuzumab.
    Waller CF; Vutikullird A; Lawrence TE; Shaw A; Liu MS; Baczkowski M; Sharma R; Barve A; Goyal P; Donnelly C; Sengupta N; Pennella EJ
    Br J Clin Pharmacol; 2018 Oct; 84(10):2336-2343. PubMed ID: 29926514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomised trial comparing the pharmacokinetics and safety of the biosimilar CT-P6 with reference trastuzumab.
    Esteva FJ; Stebbing J; Wood-Horrall RN; Winkle PJ; Lee SY; Lee SJ
    Cancer Chemother Pharmacol; 2018 Mar; 81(3):505-514. PubMed ID: 29330636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase 1 randomized study compare the pharmacokinetics, safety and immunogenicity of HLX04 to reference bevacizumab sourced from the United States, the European Union, and China in healthy Chinese male volunteers.
    Zhu X; Qian H; Sun J; Wu M; Yu C; Ding Y; Zhang X; Chai K; Li X
    Cancer Chemother Pharmacol; 2021 Sep; 88(3):465-474. PubMed ID: 34086067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phase 1 randomized study compare the pharmacokinetics, safety and immunogenicity of HLX02 to reference CN- and EU-sourced trastuzumab in healthy subjects.
    Zhu X; Ding Y; Yu Y; Wang M; Zhou W; Wang J; Zhu X; Zhang H; Wang M; Chai K; Zhang X; Luk A; Jiang W; Liu S; Zhang Q
    Cancer Chemother Pharmacol; 2021 Mar; 87(3):349-359. PubMed ID: 33169186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, double-blind, parallel-group, single-dose comparative pharmacokinetic study of DRL_TZ, a candidate biosimilar of trastuzumab, with Herceptin
    Lickliter JD; Dadhania RN; Trivedi RK; Naveen Kumar SR; Reddy PK
    Indian J Med Res; 2021 Mar; 154(3):509-519. PubMed ID: 35142643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I study comparing the biosimilarity of the pharmacokinetics and safety of recombinant humanized anti-vascular endothelial growth factor monoclonal antibody injection with Avastin
    Li H; Zhao X; Xie J; Zhu X; Su Y; He C; Ding J; Zhu M; Xu Y; Wang Y; Shan R; Liu B; Ding Y; Liu Y; Zhou H; Xie Y
    BMC Pharmacol Toxicol; 2023 May; 24(1):36. PubMed ID: 37245022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TROIKA-1: A double-blind, randomized, parallel group, study aimed to demonstrate the equivalent pharmacokinetic profile of HD201, a potential biosimilar candidate to trastuzumab, versus EU-Herceptin
    Demarchi M; Coliat P; Mclendon K; Chung Shii Hii J; Feyaerts P; Ang F; Jaison L; Deforce F; Derde MP; Kim MJ; Park LS; Detappe A; Pivot X
    Pharmacol Res Perspect; 2021 Aug; 9(4):e00839. PubMed ID: 34309241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized, double-blind, parallel-group, single‑dose, pharmacokinetic bioequivalence study of INTP24 and bevacizumab in healthy adult men.
    Singh I; Patel R; Patel A; Jose V
    Cancer Chemother Pharmacol; 2020 Aug; 86(2):193-202. PubMed ID: 32627073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I, randomized, single-dose pharmacokinetic study comparing sb8 (bevacizumab biosimilar) with reference bevacizumab in healthy volunteers.
    Shin D; Lee YJ; Choi J; Lee D; Park M; Petkova M
    Cancer Chemother Pharmacol; 2020 Oct; 86(4):567-575. PubMed ID: 32949267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Randomized, Double-Blind, Parallel-Controlled Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of SCT510 to Bevacizumab (Avastin
    Wu J; Wu G; Xie L; Lv D; Xu C; Zhou H; Wu L; Zhang J; Shentu J
    Drugs R D; 2023 Jun; 23(2):175-183. PubMed ID: 37247166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized, double-blind, single-dose study to evaluate the biosimilarity of QL1101 with bevacizumab in healthy male subjects.
    Liu YN; Huang J; Guo C; Yang S; Ye L; Wu ST; Zhang XF; Yang XY; Han CC; Pei Q; Huang L; He QN; Yang GP
    Cancer Chemother Pharmacol; 2020 Mar; 85(3):555-562. PubMed ID: 31907645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Randomized, Single-dose, Phase I Clinical Comparison of a Trastuzumab Biosimilar With a Reference Trastuzumab Formulation in Healthy Chinese Male Volunteers.
    Pu H; Jia J; Zhao C; Hou S; Guo H; Li J; Qian W; Wang H; Sun C; Zou Y
    Clin Pharmacol Drug Dev; 2023 Feb; 12(2):181-189. PubMed ID: 36317757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Randomized, Double-Blind, Parallel-Group Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of CMAB015, a Candidate Secukinumab Biosimilar, with Its Reference Product Cosentyx
    Yao F; Wang C; Ding J; Zhang Q; Zheng L; Zhang Q; Yang T; Zhang X; Shan Y; Hou S; Wang H; Zhou R; Hu W
    Drug Des Devel Ther; 2024; 18():3891-3901. PubMed ID: 39224901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and pharmacokinetics of a new biosimilar trastuzumab (HL02): a Phase I bioequivalence study in healthy Chinese men.
    Zhang H; Liu T; Wu M; Wei H; Li C; Li X; Liu J; Chen H; Ding Y; Liu L
    Expert Opin Biol Ther; 2022 Feb; 22(2):179-186. PubMed ID: 33616478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Randomized, Double-Blind, Parallel-Group, Phase 1 Clinical Trial Comparing the Pharmacokinetic, Safety, and Immunogenicity of the Biosimilar HS016 and the Originator Adalimumab in Chinese Healthy Male Subjects.
    Cao G; Yu J; Wu J; Wang J; Xue Y; Yang X; Zhang J
    Clin Pharmacol Drug Dev; 2021 Mar; 10(3):317-325. PubMed ID: 32463599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparative pharmacokinetic study of DRL_BZ, a candidate biosimilar of bevacizumab, with Avastin
    Wynne C; Schwabe C; Batra SS; Lopez-Lazaro L; Kankanwadi S
    Br J Clin Pharmacol; 2018 Oct; 84(10):2352-2364. PubMed ID: 29943831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.